Composition : Mysema-7 : Each Tablet contains Semaglutide INN 7mg.

Indications :Semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage &Administration :Semaglutide should be started with 3 mg once daily for 30 days. The 3mg dose is intended for treatment initiation and is not effective for glycemic control. After 30 days on the 3 mg dose, increase the dose to 7 mg once daily. Dose may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the7 mg dose. Taking two 7 mg tables to achieve a 14 mg dose is not recommended. If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day. Or, as directed by the registered physician.

Use in Pregnancy and Lactation :There are limited data with semaglutide use in pregnant women. Semaglutide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no data on the presence of Semaglutide in human milk, the effects on the breastfed infant, or theeffects on milk production. Discontinue Semaglutide inwomen at least 2 months before a planned pregnancydue to the long washout period for Semaglutide.

Packing : Mysema-7 : Each box contains 60’s tablets in a blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.